AbCellera Biologics Inc.

ABCL Healthcare Biotechnology

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.80 0.88 −6.94%
Market cap
$4.1B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
5/9
Altman Z
1.66
Beneish M
−1.06
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — 4 6 2 3 5
P/E ratio
— 5,890.00 5,890.00 53.87 26.00 16.95 0.00 0.00 0.00
P/S ratio
— 0.00 0.00 27.48 10.51 5.57 43.57 29.91 13.60
Altman Z-Score
— — — 23.71 9.90 7.50 3.32 1.67 1.66
P/FCF ratio
— 755.12 755.12 799.05 21.19 13.22 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
— — 0.31 11.03 9.41 9.92 6.46 5.62 4.67
P/Operating CF
— (2,371.65) (2,371.65) 5,012.52 (235.96) 87.51 (84.49) (107.80) (29.40)
Beneish M-Score
— — — 17.69 (2.71) (3.32) 2.55 (2.57) (1.06)
P/B ratio
— 1,287.81 1,287.81 7.71 3.84 2.19 1.44 0.82 1.06
Price to Tangible BV
— 1,287.81 1,287.81 9.37 4.75 2.57 1.68 0.89 1.16
EV/Sales
— 0.00 0.00 24.94 8.53 3.70 23.01 7.46 6.21
EV/EBITDA
— 0.00 0.00 35.87 14.43 7.20 0.00 0.00 0.00
EV/Operating CF
— 370.33 370.33 256.30 13.08 6.48 (19.94) (1.98) (3.55)
EV/FCF
— 747.79 747.79 725.38 17.19 8.78 (7.06) (1.13) (2.63)
Quick Ratio
— 1.83 1.37 7.80 7.53 8.03 6.86 8.93 9.60
Current Ratio
— 2.50 1.60 7.86 7.70 8.67 7.33 9.81 11.32
Net Debt/EBITDA
— 260.87 1.81 (3.68) (3.37) (3.65) 3.81 2.99 2.97
Debt/Assets
0.00% 0.00% 14.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 0.34 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.99 0.45 0.32 0.34 0.03 0.02 0.06
Operating CF/Net income
— 12.21 (1.22) 0.27 1.59 1.75 0.30 0.67 0.90
Capex/Depreciation
— (7.27) (2.16) (2.78) (3.39) (2.19) (2.51) (0.81) (1.48)
Interest Coverage
— (3.55) (19.70) 22.91 33.62 53.53 — — —
ROE
— 8.34% (65.94%) 20.43% 16.53% 14.03% (12.27%) (14.75%) (14.47%)
ROA
— 0.00% (18.83%) 16.54% 13.21% 11.09% (9.67%) (11.43%) (10.78%)
ROIC
— 0.00% (41.89%) 41.25% 46.00% 42.05% (40.43%) (48.52%) (33.25%)
Return on Tangible Assets
— 1.95% (16.72%) 11.69% 16.67% 14.10% (14.07%) (16.04%) (13.41%)
Average Days of Receivables
— 41.33 102.97 333.82 156.21 29.02 293.63 425.55 283.21
Research and Development Expense of Revenue
— 65.71% 87.09% 12.61% 16.54% 22.22% 461.95% 580.10% 248.68%
Selling, General and Administrative Expense of Revenue
— 32.42% 34.55% 6.76% 13.00% 13.75% 197.71% 296.50% 110.79%
Intangible Assets out of Total Assets
0.00 0.00 0.04 0.15 0.15 0.12 0.11 0.07 0.06
Share Based Compensation of Revenue
— 6.96% 7.66% 3.60% 8.17% 10.19% 168.79% 234.39% 74.26%
Graham Net Nets
— 0.01 0.01 0.10 0.16 0.27 0.32 0.52 0.33
Graham Number
— 0.00 0.00 9.36 6.78 7.38 0.00 0.00 0.00
Earnings Yield
— 0.02% 0.02% 1.86% 3.85% 5.90% (9.08%) (18.77%) (14.33%)
Free Cash Flow Yield
— 0.13% 0.13% 0.13% 4.72% 7.57% (7.48%) (22.04%) (17.34%)
Revenue per Share
— 0.06 0.08 1.46 1.36 1.70 0.13 0.10 0.25
Operating CF per Share
— 0.02 0.02 0.14 0.89 0.97 (0.15) (0.37) (0.44)
Capex per Share
— (0.04) (0.03) (0.09) (0.21) (0.25) (0.27) (0.27) (0.14)
Free Cash Flow per Share
— (0.01) (0.01) 0.05 0.68 0.72 (0.42) (0.64) (0.58)
Cash per Share
— 0.07 0.05 3.73 2.71 3.20 2.72 2.21 1.87
Shareholders Equity per Share
— 0.00 0.07 5.22 3.72 4.33 3.99 3.59 3.24
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 0.00 0.07 5.22 3.72 4.33 3.99 3.59 3.24
Free Cash Flow
— (1.74) (1.30) 8.02 186.13 204.70 (121.38) (186.95) (174.07)
Working Capital
— 9.00 4.75 709.84 809.12 907.17 752.97 674.76 663.93
Capital Expenditures
— (5.31) (4.00) (14.67) (58.45) (72.66) (77.51) (78.40) (42.77)
Net Current Asset Value
— 15.00 (0.60) 638.30 636.96 717.86 536.21 446.90 338.19
EV/EBIT
— 0.00 0.00 37.27 15.65 8.30 0.00 0.00 0.00
Capex to Sales
— 0.60 0.34 0.06 0.16 0.15 2.04 2.72 0.57
Price to Operating Income
— 0.00 0.00 41.06 19.29 12.49 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.12 0.22 0.29 0.15 0.15 0.11 0.28 0.07
Cash ROIC
— (12.44%) (6.13%) 0.56% 10.49% 9.54% (6.26%) (10.95%) (11.41%)
Accounts Receivable Turnover
— 4.42 5.43 2.15 2.01 4.87 1.10 0.90 1.63
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — — — 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — — 0.00 0.00 — — —
Average Receivables
— 2.00 2.14 108.26 186.91 99.58 34.59 32.10 45.95
Average Payables
— 2.50 2.29 11.39 26.11 42.26 51.04 52.29 52.89
Average Inventory
— — — — — 2.00 — — —
Average Assets
— 0.00 11.74 514.51 1,162.05 1,429.74 1,514.50 1,424.32 1,358.75
Average Common Equity
— 3.50 3.35 416.61 928.12 1,129.51 1,192.80 1,104.20 1,011.49

Fold the line items

Columns are period end dates